Chemocentryx Inc Q4 2016 Institutional Investor Sentiment Better Than Expected

September 13, 2017 - By reb123z

 Chemocentryx Inc  Q4 2016 Institutional Investor Sentiment  Better Than Expected

Sentiment for Chemocentryx Inc (NASDAQ:CCXI)

Chemocentryx Inc (NASDAQ:CCXI) institutional sentiment increased to 2.67 in 2016 Q4. Its up 1.64, from 1.03 in 2016Q3. The ratio improved, as 56 institutional investors started new and increased holdings, while 21 sold and decreased stakes in Chemocentryx Inc. The institutional investors in our partner’s database now have: 23.08 million shares, up from 22.56 million shares in 2016Q3. Also, the number of institutional investors holding Chemocentryx Inc in their top 10 holdings was flat from 1 to 1 for the same number . Sold All: 4 Reduced: 17 Increased: 36 New Position: 20.

ChemoCentryx, Inc. is a biopharmaceutical company. The company has market cap of $359.70 million. The Firm is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. It currently has negative earnings. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

About 26,342 shares traded. ChemoCentryx Inc (NASDAQ:CCXI) has risen 60.64% since September 13, 2016 and is uptrending. It has outperformed by 43.94% the S&P500.

Bvf Inc Il holds 11.59% of its portfolio in ChemoCentryx Inc for 7.80 million shares. Sio Capital Management Llc owns 325,250 shares or 1.4% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 1.19% invested in the company for 270,000 shares. The Connecticut-based P.A.W. Capital Corp has invested 1% in the stock. Nantahala Capital Management Llc, a Connecticut-based fund reported 467,455 shares.#img1#

Since January 1, 0001, it had 0 insider buys, and 1 sale for $29,228 activity.

ChemoCentryx Inc (NASDAQ:CCXI) Ratings Coverage

Ratings analysis reveals 33% of ChemoCentryx’s analysts are positive. Out of 3 Wall Street analysts rating ChemoCentryx, 1 give it “Buy”, 1 “Sell” rating, while 1 recommend “Hold”. CCXI was included in 5 notes of analysts from September 3, 2015. Zacks downgraded ChemoCentryx Inc (NASDAQ:CCXI) on Thursday, September 3 to “Sell” rating. The firm earned “Hold” rating on Tuesday, August 8 by Cowen & Co. JMP Securities maintained ChemoCentryx Inc (NASDAQ:CCXI) on Thursday, August 10 with “Buy” rating. The firm has “Sell” rating by Zacks given on Monday, September 21. JMP Securities initiated the shares of CCXI in report on Tuesday, February 21 with “Mkt Outperform” rating.

Another recent and important ChemoCentryx Inc (NASDAQ:CCXI) news was published by Globenewswire.com which published an article titled: “ChemoCentryx to Present at Three Upcoming Investor Conferences” on September 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.